Literature DB >> 10987833

Purine uptake and release in rat C6 glioma cells: nucleoside transport and purine metabolism under ATP-depleting conditions.

C J Sinclair1, C G LaRivière, J D Young, C E Cass, S A Baldwin, F E Parkinson.   

Abstract

Adenosine, through activation of membrane-bound receptors, has been reported to have neuroprotective properties during strokes or seizures. The role of astrocytes in regulating brain interstitial adenosine levels has not been clearly defined. We have determined the nucleoside transporters present in rat C6 glioma cells. RT-PCR analysis, (3)H-nucleoside uptake experiments, and [(3)H]nitrobenzylthioinosine ([(3)H]NBMPR) binding assays indicated that the primary functional nucleoside transporter in C6 cells was rENT2, an equilibrative nucleoside transporter (ENT) that is relatively insensitive to inhibition by NBMPR. [(3)H]Formycin B, a poorly metabolized nucleoside analogue, was used to investigate nucleoside release processes, and rENT2 transporters mediated [(3)H]formycin B release from these cells. Adenosine release was investigated by first loading cells with [(3)H]adenine to label adenine nucleotide pools. Tritium release was initiated by inhibiting glycolytic and oxidative ATP generation and thus depleting ATP levels. Our results indicate that during ATP-depleting conditions, AMP catabolism progressed via the reactions AMP --> IMP --> inosine --> hypoxanthine, which accounted for >90% of the evoked tritium release. It was surprising that adenosine was not released during ATP-depleting conditions unless AMP deaminase and adenosine deaminase were inhibited. Inosine release was enhanced by inhibition of purine nucleoside phosphorylase; ENT2 transporters mediated the release of adenosine or inosine. However, inhibition of AMP deaminase/adenosine deaminase or purine nucleoside phosphorylase during ATP depletion produced release of adenosine or inosine, respectively, via the rENT2 transporter. This indicates that C6 glioma cells possess primarily rENT2 nucleoside transporters that function in adenosine uptake but that intracellular metabolism prevents the release of adenosine from these cells even during ATP-depleting conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987833     DOI: 10.1046/j.1471-4159.2000.0751528.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

2.  Nucleoside transporter subtype expression: effects on potency of adenosine kinase inhibitors.

Authors:  C J Sinclair; A E Powell; W Xiong; C G LaRivière; S A Baldwin; C E Cass; J D Young; F E Parkinson
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.

Authors:  Fernanda B Morrone; Maria C Jacques-Silva; Ana P Horn; Andressa Bernardi; Gilberto Schwartsmann; Richard Rodnight; Guido Lenz
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

5.  Hypoxanthine transport in human glioblastoma cells and effect on cell susceptibility to methotrexate.

Authors:  Wei Kong; Joanne Wang
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

6.  Biosensor measurement of purine release from cerebellar cultures and slices.

Authors:  Mark Wall; Robert Eason; Nicholas Dale
Journal:  Purinergic Signal       Date:  2010-05-25       Impact factor: 3.765

7.  Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells.

Authors:  Richard G E Archer; Václav Pitelka; James R Hammond
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

8.  Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG membrane transport.

Authors:  A R Buursma; I J van Dillen; A van Waarde; W Vaalburg; G A P Hospers; N H Mulder; E F J de Vries
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

9.  [18F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [18F]FDG in human xenograft models.

Authors:  Narinée Hovhannisyan; Fabien Fillesoye; Stéphane Guillouet; Méziane Ibazizene; Jérôme Toutain; Fabienne Gourand; Samuel Valable; Benoit Plancoulaine; Louisa Barré
Journal:  Theranostics       Date:  2018-08-10       Impact factor: 11.556

Review 10.  The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation.

Authors:  Valentina Di Liberto; Giuseppa Mudò; Roberta Garozzo; Monica Frinchi; Víctor Fernandez-Dueñas; Patrizia Di Iorio; Renata Ciccarelli; Francesco Caciagli; Daniele F Condorelli; Francisco Ciruela; Natale Belluardo
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.